Celularity Inc. (CELU)
NASDAQ: CELU · Real-Time Price · USD
1.720
-0.010 (-0.58%)
Apr 1, 2025, 4:00 PM EDT - Market closed
Celularity Employees
Celularity had 120 employees as of December 31, 2023. The number of employees decreased by 105 or -46.67% compared to the previous year.
Employees
120
Change (1Y)
-105
Growth (1Y)
-46.67%
Revenue / Employee
$401,667
Profits / Employee
-$292,100
Market Cap
38.67M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 120 | -105 | -46.67% |
| Dec 31, 2022 | 225 | 0 | - |
| Dec 31, 2021 | 225 | 63 | 38.89% |
| Dec 31, 2020 | 162 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CELU News
- 5 weeks ago - Celularity Receives FDA Tissue Reference Group Recommendation Letters for its Natalin and Acelagraft™ Wound Care Products - GlobeNewsWire
- 5 weeks ago - Celularity Enters Strategic Collaboration Agreement with Clinical Stage Cell Therapy Company - GlobeNewsWire
- 4 months ago - Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter - GlobeNewsWire
- 4 months ago - Celularity Reports Over Sevenfold Growth in Net Product Sales through Third Quarter 2024 Compared to Third Quarter 2023 - GlobeNewsWire
- 4 months ago - Celularity Inc. Announces Receipt of Nasdaq Notification - GlobeNewsWire
- 4 months ago - Celularity's Strategic Partner Announces Groundbreaking for State-of-the-Art Stem Cell & Regenerative Medicine Center in Asia Pacific - GlobeNewsWire
- 5 months ago - Celularity Files Appeal Request and Amended Compliance Plan with Nasdaq Hearings Panel - GlobeNewsWire
- 5 months ago - Celularity Inc. Receives Notice from Nasdaq; Confirms Intention to File an Appeal - GlobeNewsWire